Arcus: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets

Core Insights - Arcus Biosciences, Inc. (NYSE: RCUS) is considered to be undervalued, with the share price being described as "too cheap to ignore" [1] Company Analysis - The company operates in the biotech sector, focusing on clinical trials and drug development [1] - The author has a PhD in biochemistry and extensive experience in analyzing biotech companies, indicating a strong foundation for evaluating the company's potential [1] Investment Perspective - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls [1]